Nacimbio Holding (operator of the National Immunization Schedule) has begun clinical trials of the world's first combined vaccine for the prevention of influenza and coronavirus infection — "Ultrix Combi".
Clinical trials will study the safety, immunogenicity, and tolerability of the vaccine with the participation of 370 volunteers. Prior to this, the developers of the drug, Nacimbio and Artgen Biotech, conducted all the necessary preclinical studies on animals. Permission for their conduct was granted by the Ministry of Health of the Russian Federation.
Including the combined vaccine in the vaccination schedule will reduce the total healthcare costs for vaccination against influenza and COVID separately, increase the effectiveness of the vaccination campaign, and increase population immunity.
The Ultrix Combi vaccine contains components to protect against four seasonal strains of influenza viruses, as well as a component that provides protection against the SARS-CoV-2 coronavirus. The antigen for immunization against COVID and the technological platform on which the vaccine is based were developed by companies of the Artgen Biotech group.
Read more on the topic:
Rostec will produce more than 70 million doses of flu vaccines
